From Podium To Practice – Breast Cancer ESMO Part 1
In this overview, Dr. Wassim Mchayleh breaks down the ASCENT-03 trial, highlighting the rationale for Trop-2–directed ADC therapy, key eligibility criteria, and how this study may reshape treatment sequencing for HR+/HER2- metastatic breast cancer following endocrine therapy and CDK4/6 inhibitors. Sponsored By Gilead.